IO Biotech

IO Biotech OCF Margin

Operating Cash Flow Margin of IO Biotech (IOBT) as of Oct 19, 2026.

OCF Margin

-

Last updated:

Operating Cash Flow Margin of IO Biotech is 2026 - . Operating Cash Flow Margin of IO Biotech was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech Inc, based in Copenhagen, Denmark, operates in the Health Care sector, specializing in Biotechnology. The company develops immune modulating cancer therapies using its T-win technology platform, focusing on disrupting tumor-induced immunosuppression. Its lead product candidate, IO102-IO103, targets immunosuppressive proteins like IDO and PD-L1. Founded as a spin-off from the National Cancer Center Immune Therapy at Herlev University Hospital, IO Biotech has 57 employees and is listed on the stock exchange since November 5, 2021. IO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IO Biotech stock

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin IO Biotech since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's IO Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — IO Biotech

All Key Metrics — IO Biotech